Xylometazoline
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Common Cold
Conditions
Common Cold
Trial Timeline
Mar 1, 2007 → Apr 1, 2007
NCT ID
NCT00452270About Xylometazoline
Xylometazoline is a phase 3 stage product being developed by Novartis for Common Cold. The current trial status is completed. This product is registered under clinical trial identifier NCT00452270. Target conditions include Common Cold.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00452270 | Phase 3 | Completed |
Competing Products
20 competing products in Common Cold